Cat. #154631
ZR-75-1 HRAS [ZR-HRAS pool B] cell line
Cat. #: 154631
Sub-type: Continuous
Unit size: 1x10^6 cells / vial
Availability: 3-4 weeks
Organism: Human
Tissue: Breast
Disease: Cancer
Model: Cancer Model
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Lambert Dorssers
Institute: Erasmus University Medical Center (Erasmus MC)
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: ZR-75-1 HRAS [ZR-HRAS pool B] cell line
- Alternate name: HRas Proto-Oncogene, GTPase; Transforming Protein P21
- Cancer: Gynaecologic cancer
- Cancers detailed: Mammary ductal carcinoma
- Research fields: Cancer;Drug development
- Tool sub type: Continuous
- Parental cell: ZR-75-1
- Organism: Human
- Tissue: Breast
- Disease: Cancer
- Model: Cancer Model
- Description: Breast cancer is widely and effectively treated with endocrine treatment. However, in many cases the tumours will eventually progress into an estrogen-independent and therapy-resistant phenotype.Seven genes including AKT1, AKT2, BCAR1, BCAR2, BCAR3, EGFR2 and GRB7 have been shown to directly underlie estrogen independence in human breast cancer cells. This cell line is part of a panel of 16 cell lines (Cat No 154621-154635, 154642) which have been transfected with these genes, plus the parental (Cat No 154547).This cell line is a powerful tool for studying the molecular and cellular mechanisms of breast tumour progression, therapy resistance and to test the effectiveness of novel drugs to combat different modes of anti-estrogen insensitivity
- Production details: Expression constructs with HRAS were transfected into ZR-75-1 cells using FuGENE 6 and selected with G418. After selection for G418 resistance colonies were expanded
- Biosafety level: 1
Target Details
- Target: HRAS
Applications
- Application notes: The cell line is resistant to Geneticin, which may be included in the culture medium to ensure that the expression vector is retained by the cells.
Handling
- Format: Frozen
- Growth medium: RPMI 1640 medium supplemented with 10% heat-inactivated bovine serum (RBCS) and 1 nM 17?-estradiol
- Unit size: 1x10^6 cells / vial
- Shipping conditions: Dry ice
- Storage conditions: Liquid Nitrogen
- Mycoplasma free: Yes
References
- van Agthoven et al. 2010. Endocr Relat Cancer. 17(1):215-30. PMID: 19966015.
